Varespladib

DB11909InvestigationalSmall molecule

Varespladib has been investigated for the treatment and prevention of Sickle Cell Disease, Vaso-occlusive Crisis, and Acute Coronary Syndrome.

Chemical structure of Varespladib
Mechanism
Curator reviewed
Formula / weight
C21H20N2O5 · 380.4 g/mol (avg)
Code names
LY-315920

Resolves to

Compound
UNII2Q3P98DATHCAS172732-68-2ChEMBLCHEMBL148674PubChem155815
Structure
InChIKeyBHLXTPHDSZUFHR-UHFFFAOYSA-NSMILESCCC1=C(C(=O)C(N)=O)C2=C(OCC(O)=O)C=CC=C2N1CC1=CC=CC=C1
Targets
P14555PLA2G2AP04054PLA2G1B

What you can answer from here — as of September 16, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
1Clinical trialPhase, status and sponsor resolved per trial
Sign in
5+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Varespladib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In